The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Open accessAbstract
BACKGROUND: A low plasma level of low-density lipoprotein (LDL) cholesterol is associated with reduced risk of coronary heart disease (CHD), but the effect of lifelong reductions in plasma LDL cholesterol is not known. We examined the effect of DNA-sequence variations that reduce plasma levels of LDL cholesterol on the incidence of coronary events in a large population. METHODS: We compared the incidence of CHD (myocardial infarction, fatal CHD, or coronary revascularization) over a 15-year interval in the Atherosclerosis Risk in Communities study according to the presence or absence of sequence variants in the proprotein convertase subtilisin/kexin type 9 serine protease gene (PCSK9) that are associated with reduced plasma levels of LDL cholesterol. RESULTS: Of the 3363 black subjects examined, 2.6 percent had nonsense mutations in PCSK9; these mutations were associated with a 28 percent reduction in mean LDL cholesterol and an 88 percent reduction in the risk of CHD (P=0.008 for the reduction; hazard ratio, 0.11; 95 percent confidence interval, 0.02 to 0.81; P=0.03). Of the 9524 white subjects examined, 3.2 percent had a sequence variation in PCSK9 that was associated with a 15 percent reduction in LDL cholesterol and a 47 percent reduction in the risk of CHD (hazard ratio, 0.50; 95 percent confidence interval, 0.32 to 0.79; P=0.003). CONCLUSIONS: These data indicate that moderate lifelong reduction in the plasma level of LDL cholesterol is associated with a substantial reduction in the incidence of coronary events, even in populations with a high prevalence of non-lipid-related cardiovascular risk factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Proprotein convertase subtilisin-kexin type 9 (PCSK9) promotes degradation of LDL receptors, thereby diminishing the clearance of LDL from the circulation. 6”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 2005, a causative association was established between the presence of loss-of-function mutations in PCSK9 and lifelong reductions in LDL-C associated with lower CHD risk (3).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic studies have shown that carriage of PCSK9 loss-of-function alleles is associated with lower LDL cholesterol levels and a reduced risk of myocardial infarction.7,8”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that drugs that ultimately reduce LDL-C level predominantly through upregulation of LDL receptor expression should, barring any off-target adverse effects, lead to clinical benefit in proportion to the degree of LDL-C reduction.64”
From Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis (2016) · cites this paper as [64]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some of the most important human metabolic disease genes have been identified using germline genetic methods such as GWAS and whole exome sequencing42-44.”
From Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease (2023) · cites this paper as [44]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike gain-of-function PCSK9 variants (7), loss-of-function (LOF) variants enhance LDLR levels and promote LDLc clearance (4, 8).”
From Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“mutations conveying gain or loss of function of PCSK9 result in a higher or lower level of LDL cholesterol, respectively, which in turn is associated with a corresponding higher 7 or lower 6 risk of incident coronary heart disease.”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Whereas PCSK9 loss-of-function mutations carriers with lifelong reductions in LDL-C and coronary heart disease incidence, were not initially found at significantly reduced risk of stroke (3, 72), a much larger study of the UK Biobank database described the first genetic evidence of a protective effect of the R46L loss-of-function mutation on PCSK9 on ischemic stroke (73).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [3]
In the citing paper
“and that lowering LDL-C reduces the risk of ASCVD proportionally to the absolute achieved reduction in LDL-C [2,51].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [51]
In the citing paper
“The remarkable consistency among these studies, in addition to biological and experimental evidence, provides compelling evidence that LDL-C is causally associated with the risk of ASCVD”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [51]
In the citing paper
“Both studies had relatively short follow-up periods and the evidence from statin trials indicates that the clinical benefits of LDL-lowering may only emerge after about 1 year [51], so these trials may have underestimated the potential impact of longer-term treatment [120,290].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [51]
In the citing paper
“These developments have enabled researchers to bridge the gap between the monogenic and polygenic realms, identifying common variant modifiers of monogenic phenotypes contributing to the variable expression of rare, large-effect alleles26,93, and low-frequency and rare variants that influence common multifactorial traits94,95.”
From A brief history of human disease genetics (2020) · cites this paper as [95]
In the citing paper
“At the same time, it has become increasingly evident now that not only the magnitude of LDL-C lowering is important but that the duration of exposure to elevated LDL-C levels is equally important [11,16,38].”
In the citing paper
“Additionally, increasing evidence also suggests that the duration of exposure to low LDL-C levels may be as important as the magnitude of LDL-C lowering [11][12][13][14][15][16].”
In the citing paper
“The exceptionally low rates of CV events observed in patients carrying mutations in PCSK9 or other similar genes despite only modestly low LDL-C levels strongly support this notion [11].”
In the citing paper
“Hobbs and Cohen sequenced the gene (126, 127) and identified low-frequency common variants (0.5 to 1%), which allowed epidemiological research documenting a protective effect on myocardial infarction (128).”
From Genetic Mapping in Human Disease (2008) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES
THE ARIC INVESTIGATORS (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115184 · Cited by 3,510
(1989) · PubMed · Cited by 3,139
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Self-citationSeidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
CORONARY DISEASE AMONG UNITED STATES SOLDIERS KILLED IN ACTION IN KOREA
Enos, W. F. (1953) · JAMA · doi:10.1001/jama.1953.03690120006002 · Cited by 891
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,025
Inclisiran—New hope in the management of lipid disorders?
Dyrbuś, K., Gąsior, M., Penson, P., Ray, K. K., & Banach, M. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.11.001 · Cited by 120
PCSK9 as a therapeutic target of dyslipidemia
Seidah, N. G. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220802600715 · Cited by 110
Tibolla, G., Norata, G. D., Artali, R., Meneghetti, F., & Catapano, A. L. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.06.002 · Cited by 120
Guey, L. T., Kravić, J., Melander, O., Burtt, N. P., Laramie, J. M., Lyssenko, V., Jonsson, A. E., Lindholm, E., Tuomilehto, J., Isomaa, B., et al. (2011) · Genetic Epidemiology · doi:10.1002/gepi.20572 · Cited by 119
Cardiovascular Precision Medicine in the Genomics Era
Dainis, A., & Ashley, E. A. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.01.003 · Cited by 119
Genome Editing: A New Approach to Human Therapeutics
Porteus, M. H. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124454 · Cited by 118
Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation
Seidah, N. G., Poirier, S., Denis, M., Parker, R., Miao, B., Mapelli, C., Prat, A., Wassef, H., Davignon, J., Hajjar, K. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041865 · Cited by 117
Leiter, L. A., Teoh, H., Kallend, D., Wright, R. S., Landmesser, U., Wijngaard, P. L. J., Kastelein, J. J. P., & Ray, K. K. (2019) · Diabetes Care · doi:10.2337/dc18-1491 · Cited by 117
Lu, Y., Cui, X., Zhang, L., Wang, X., Xu, Y., Qin, Z., Liu, G., Wang, Q., Tian, K., Lim, K. S., et al. (2022) · Aging and Disease · doi:10.14336/ad.2021.0929 · Cited by 117
Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations
Hetherington, I., & Totary-Jain, H. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.024 · Cited by 119
Tavori, H., Giunzioni, I., Predazzi, I. M., Plubell, D. L., Shivinsky, A., Miles, J., DeVay, R. M., Hong, L., Rashid, S., Linton, M. F., et al. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw053 · Cited by 117
Seidah, N. G., Abifadel, M., Prost, S., Boileau, C., & Prat, A. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.012989 · Cited by 116
Abifadel, M., Guérin, M., Benjannet, S., Rabès, J., Goff, W. L., Julia, Z., Hamelin, J., Carreau, V., Varret, M., Bruckert, É., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.04.006 · Cited by 116
Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
German, C. A., & Shapiro, M. D. (2019) · BioDrugs · doi:10.1007/s40259-019-00399-6 · Cited by 117
Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol
Ghosh, M., Gälman, C., Rudling, M. J., & Angelin, B. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m055780 · Cited by 116
Venous Thromboembolism and Risk of Idiopathic Interstitial Pneumonia: A Nationwide Study
Sode, B. F., Dahl, M., Nielsen, S. F., & Nordestgaard, B. G. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200912-1951oc · Cited by 115
Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Brautbar, A., & Ballantyne, C. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.2 · Cited by 115
Cariou, B., Langhi, C., Bras, M. L., Bortolotti, M., Lê, K., Theytaz, F., May, C. L., Guyomarch, B., Zaïr, Y., Kreis, R., et al. (2013) · Nutrition & Metabolism · doi:10.1186/1743-7075-10-4 · Cited by 115
Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stančáková, A., Chen, Y., Varga, T. V., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3744 · Cited by 115
Self-citationCRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulation
Sun, W., Wang, J., Hu, Q., Zhou, X., Khademhosseini, A., & Gu, Z. (2020) · Science Advances · doi:10.1126/sciadv.aba2983 · Cited by 115
Roychowdhury, T., Klarin, D. M., Levin, M. G., Spin, J. M., Rhee, Y. H., Deng, A. C., Headley, C. A., Tsao, N. L., Gellatly, C., Zuber, V., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01510-y · Cited by 115
Lambert, G. C., Jarnoux, A. L., Pineau, T., Pape, O., Chétiveaux, M., LABOISSE, C. L., Krempf, M., & Costet, P. (2006) · Endocrinology · doi:10.1210/en.2006-0098 · Cited by 115
PCSK9 is expressed in pancreatic δ-cells and does not alter insulin secretion
Langhi, C., May, C. L., Gmyr, V., Vandewalle, B., Kerr-Conte, J. A., Krempf, M., Pattou, F. N., Costet, P., & Cariou, B. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.138 · Cited by 115
Lawlor, D. A. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dys209 · Cited by 114
Packard, C. J., Chapman, M. J., Sibartie, M., Laufs, U., & Masana, L. (2021) · Heart · doi:10.1136/heartjnl-2020-318760 · Cited by 114
Ridker, P. M., Rifai, N., Bradwin, G., & Rose, L. M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv568 · Cited by 113
The abnormal lipid profile in obesity and coronary heart disease (CHD) in Pakistani subjects
Shabana, S., Shahid, S. U., & Sarwar, S. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01248-0 · Cited by 113
The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis
Mousavi, S. A., Berge, K. E., & Leren, T. P. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02167.x · Cited by 113
Wu, Q., Wang, Q., Fu, J., & Ren, R. (2019) · Food & Function · doi:10.1039/c8fo02375a · Cited by 112
Chen, L., Ma, M.-Y., Sun, M., Jiang, L.-Y., Zhao, X.-T., Fang, X.-X., Lam, S. M., Shui, G., Luo, J., Shi, X.-J., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.ra119000201 · Cited by 114
Robinson, J. G. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.2.139 · Cited by 112
Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization
Smith, G. D., Timpson, N. J., & Ebrahim, S. B. J. (2008) · Annals of Medicine · doi:10.1080/07853890802010709 · Cited by 112
Kratzer, A., Giral, H., & Landmesser, U. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu139 · Cited by 112
Mayne, J., Dewpura, T., Raymond, A., Bernier, L., Cousins, M., Ooi, T. C., Davignon, J., Seidah, N. G., Mbikay, M., & Chrétien, M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.165191 · Cited by 111
Tang, C. S.-M., Zhang, H., Cheung, C. Y. Y., Xu, M., Ho, J. C.-Y., Zhou, W., Cherny, S. S., Zhang, Y., Holmen, O. L., Au, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms10206 · Cited by 111
Mechanisms of Mendelian dominance
Veitia, R. A., Caburet, S., & Birchler, J. A. (2017) · Clinical Genetics · doi:10.1111/cge.13107 · Cited by 111
Genetics of coronary artery disease in the post‐GWAS era
Chen, Z., & Schunkert, H. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13362 · Cited by 111
Coronary Artery Disease Genetics Enlightened by Genome-Wide Association Studies
Kessler, T., & Schunkert, H. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.04.001 · Cited by 111
Tremblay, F., Xiong, Q., Shah, S. S., Ko, C., Kelly, K., Morrison, M. S., Giancarlo, C., Ramírez, R. N., Hildebrand, E. M., Voytek, S. B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03508-x · Cited by 116
A treasure trove for lipoprotein biology
Lusis, A. J., & Pajukanta, P. (2008) · Nature Genetics · doi:10.1038/ng0208-129 · Cited by 110
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
Sliz, E., Kettunen, J., Holmes, M. V., Williams, C. O., Boachie, C., Wang, Q., Männikkö, M., Sebert, S., Walters, R., Lin, K., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034942 · Cited by 109
Almontashiri, N. A. M., Vilmundarson, R. O., Ghasemzadeh, N., Dandona, S., Roberts, R., Quyyumi, A. A., Chen, H., & Stewart, A. F. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106294 · Cited by 109
Abifadel, M., Elbitar, S., Khoury, P. E., Ghaleb, Y., Chemaly, M., Moussalli, M.-L., Rabès, J., Varret, M., & Boileau, C. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0439-8 · Cited by 109
Werner, C. M., Hoffmann, M. M., Winkler, K., Böhm, M., & Laufs, U. (2014) · Vascular Pharmacology · doi:10.1016/j.vph.2014.03.004 · Cited by 109
Strategic Approaches to Unraveling Genetic Causes of Cardiovascular Diseases
Marian, A. J., & Belmont, J. W. (2011) · Circulation Research · doi:10.1161/circresaha.110.236067 · Cited by 109
Evolution and Emergence of Therapeutic Monoclonal Antibodies
Foltz, I. N., Karow, M. L., & Wasserman, S. M. (2013) · Circulation · doi:10.1161/circulationaha.113.002033 · Cited by 109
Robinson, J. G., Williams, K. J., Gidding, S. S., Borén, J., Tabas, I. A., Fisher, E. A. A., Packard, C. J., Pencina, M. J., Fayad, Z. A., Mani, V., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009778 · Cited by 109
Browning, J. D., & Horton, J. D. (2010) · Journal of Lipid Research · doi:10.1194/jlr.p009860 · Cited by 109
Human genetics of infectious diseases: Unique insights into immunological redundancy
Casanova, J., & Abel, L. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.12.008 · Cited by 108
Evolution of sequence-defined highly functionalized nucleic acid polymers
Chen, Z., Lichtor, P. A., Berliner, A. P., Chen, J. C., & Liu, D. R. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0008-9 · Cited by 108
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 108
PCSK9 Inhibition: From Current Advances to Evolving Future
Liu, C., Chen, J., Chen, H., Zhang, T., He, D., Luo, Q., Chi, J., Hong, Z., Liao, Y., Zhang, S., et al. (2022) · Cells · doi:10.3390/cells11192972 · Cited by 108
Schmidt, R. J., Beyer, T. P., Bensch, W. R., Qian, Y., Lin, A., Kowala, M. C., Alborn, W. E., Konrad, R. J., & Cao, G. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.004 · Cited by 108
Ni, Y. G., Condra, J. H., Orsatti, L., Shen, X., Di Marco, S., Pandit, S., Bottomley, M. J., Ruggeri, L., Cummings, R. T., Cubbon, R. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113035 · Cited by 107
Mark, H. (2017) · doi:10.1016/j.jacc.2017.10.001 · Cited by 107
Zhang, L., McCabe, T. J. D., Condra, J. H., Ni, Y. G., Peterson, L. B., Wang, W., Strack, A. M., Wang, F., Pandit, S., Hammond, H. A., et al. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.3524 · Cited by 106
Inclisiran for the Treatment of Cardiovascular Disease: the Orion Clinical Development Program
Stoekenbroek, R. M., Kallend, D. G., Wijngaard, P. L. J., & Kastelein, J. J. P. (2018) · Future Cardiology · doi:10.2217/fca-2018-0067 · Cited by 106
Cardiovascular Risk Factors in Childhood and Adulthood and Cardiovascular Disease in Middle Age
Kartiosuo, N., Raitakari, O. T., Juonala, M., Viikari, J. S. A., Sinaiko, A. R., Venn, A., Jacobs, D. R., Urbina, E. M., Woo, J. G., Steinberger, J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.18148 · Cited by 106
Management of patients with familial hypercholesterolaemia
Reiner, Ž. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.92 · Cited by 106
Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity
Fan, D., Yancey, P. G., Qiu, S., Ding, L., Weeber, E. J., Linton, M. F., & Fazio, S. (2008) · Biochemistry · doi:10.1021/bi7016359 · Cited by 106
Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
Steinberg, D. H., & Witztum, J. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904560106 · Cited by 106
Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
Shapiro, M. D., & Fazio, S. (2017) · F1000Research · doi:10.12688/f1000research.9845.1 · Cited by 103
Apolipoprotein B-containing lipoproteins in atherogenesis
Borén, J., Packard, C. J., & Binder, C. J. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01111-0 · Cited by 110
Lawlor, D. A., Harbord, R. M., Timpson, N. J., Lowe, G. D. O., Rumley, A., Gaunt, T. R., Baker, I. A., YARNELL, J. W. G., Mika Kivimaki, B., Meena Kumari, B., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003011 · Cited by 105
Sharotri, V., Collier, D. M., Olson, D. R., Zhou, R., & Snyder, P. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.363382 · Cited by 104
The PCSK9 revolution: Current status, controversies, and future directions
Warden, B. A., Fazio, S., & Shapiro, M. D. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.05.007 · Cited by 103
Proprotein Convertase Subtilisin/Kexin Type 9
Macchi, C., Ferri, N., Sirtori, C. R., Corsini, A., Banach, M., & Ruscica, M. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.04.016 · Cited by 103
Electronic Cigarette Use and the Risk of Cardiovascular Diseases
Espinoza-Derout, J., Shao, X. M., Lao, C. J., Hasan, K. M., Rivera, J. C., Jordan, M. C., Echeverria, V., Roos, K. P., Sinha-Hikim, A. P., & Friedman, T. C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.879726 · Cited by 103
Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9
Kourimate, S., May, C. L., Langhi, C., Jarnoux, A. L., Ouguerram, K., Zaïr, Y., Nguyen, P., Krempf, M., Cariou, B., & Costet, P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705831200 · Cited by 103
Genetics of Familial Hypercholesterolemia
Brautbar, A., Leary, E. J. W., Rasmussen, K., Wilson, D. P., Steiner, R. D., & Virani, S. S. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0491-z · Cited by 103
Genetics of Cardiovascular Diseases
Cambien, F., & Tiret, L. (2007) · Circulation · doi:10.1161/circulationaha.106.661751 · Cited by 103
Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Steinberg, D. H., Glass, C. K., & Witztum, J. L. (2008) · Circulation · doi:10.1161/circulationaha.107.753152 · Cited by 102
Petersen, D. N., Hawkins, J., Ruangsiriluk, W., Stevens, K. A., Maguire, B. A., O’Connell, T. N., Rocke, B. N., Boehm, M., Ruggeri, R. B., Rolph, T., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.08.016 · Cited by 102
Can LDL cholesterol be too low? Possible risks of extremely low levels
OLSSON, A. G., Angelin, B., Assmann, G., Binder, C. J., Björkhem, I., Cedazo-Mı́nguez, Á., Cohen, J. C., von Eckardstein, A., Farinaro, E., Müller‐Wieland, D., et al. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12614 · Cited by 102
Self-citationSahebkar, A., Simental‐Mendía, L. E., Guerrero‐Romero, F., Golledge, J., & Watts, G. F. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12536 · Cited by 101
Primary Prevention of Subclinical Atherosclerosis in Young Adults
Devesa, A., Ibáñez, B., Malick, W. A., Tinuoye, E. O., Bustamante, J., Peyra, C., Rosenson, R. S., Bhatt, D. L., Stone, G. W., & Fuster, V. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.09.817 · Cited by 101
Oestrogen-modulated gene expression in the human endometrium
Punyadeera, C., Dassen, H. H. N. M., Klomp, J. P. G., Dunselman, G. A. J., Kamps, R., Dijcks, F. A., EDERVEEN, A. G. H., de Goeij, A. F. P. M., & Groothuis, P. G. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4435-y · Cited by 101
Persson, L., Henriksson, P., Westerlund, E., Hovatta, O., Angelin, B., & Rudling, M. J. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.242461 · Cited by 100
Jang, H., Lee, S. E., Yang, J., Lee, H.-C., Shin, D., Lee, H., Lee, J., Jin, S., Kim, S., Lee, S. J., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz566 · Cited by 100
New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs
Norata, G. D., Ballantyne, C. M., & Catapano, A. L. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht088 · Cited by 99
Abifadel, M., Rabès, J.-P., Jambart, S., Halaby, G., Gannagé-Yared, M.-H., Sarkis, A., Beaino, G., Varret, M., Salem, N., Corbani, S., et al. (2009) · Human Mutation · doi:10.1002/humu.21002 · Cited by 99
Inclisiran: a new promising agent in the management of hypercholesterolemia
Kosmas, C. E., Muñoz Estrella, A., Sourlas, A., Silverio, D., Hilario, E., Montan, P. D., & Guzman, E. (2018) · Diseases · doi:10.3390/diseases6030063 · Cited by 99
PCSK9: From discovery to therapeutic applications
Farnier, M. (2014) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.10.007 · Cited by 99
Genetic Basis of Atherosclerosis: Insights From Mice and Humans
Stylianou, I. M., Bauer, R. C., Reilly, M. P., & Rader, D. J. (2012) · Circulation Research · doi:10.1161/circresaha.110.230854 · Cited by 99
Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9
Miao, J., Manthena, P. V., Haas, M. E., Ling, A. V., Shin, D., Graham, M. J., Crooke, R. M., Liu, J., & Biddinger, S. B. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305688 · Cited by 99
Genomic Predictors of Asthma Phenotypes and Treatment Response
Hernandez‐Pacheco, N., Pino-Yanes, M. D. M., & Flores, C. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00006 · Cited by 99
Targeting RNA With Antisense Oligonucleotides and Small Interfering RNA in Dyslipidemias
Katzmann, J. L., Packard, C. J., Chapman, M. J., Katzmann, I., & Laufs, U. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.070 · Cited by 99
PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain
Liu, M., Wu, G., Baysarowich, J., Kavana, M., Addona, G. H., Bierilo, K. K., Mudgett, J. S., Pavlovic, G., Sitlani, A., Renger, J. J., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006635 · Cited by 98
PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
Shimada, Y. J., & Cannon, C. P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv174 · Cited by 98
Liu, A., & Frostegård, J. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12758 · Cited by 98
Personalized Intervention Based on Early Detection of Atherosclerosis
Nielsen, R. V., Fuster, V., Bundgaard, H., Fuster, J. J., Johri, A. M., Kofoed, K. F., Douglas, P. S., Diederichsen, A. C. P., Shapiro, M. D., Nicholls, S. J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.053 · Cited by 98
Familial hypercholesterolemia: A review
Varghese, M. J. (2014) · Annals of Pediatric Cardiology · doi:10.4103/0974-2069.132478 · Cited by 98
Gidding, S. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.21.2341 · Cited by 98
Bjornstad, P., Donaghue, K. C., & Maahs, D. M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30035-4 · Cited by 99
van Poelgeest, E. P., Hodges, M. R., Moerland, M., Tessier, Y., Levin, A. A., Persson, R., Lindholm, M., Erichsen, K. D., Ørum, H., Cohen, A. F., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12738 · Cited by 97
Scartezini, M., Hubbart, C., Whittall, R., Cooper, J. A., Neil, A., & Humphries, S. E. (2007) · Clinical Science · doi:10.1042/cs20070150 · Cited by 97
Lawlor, D. A., Nordestgaard, B. G., Benn, M., Zuccolo, L., Tybjærg‐Hansen, A., & Smith, G. D. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht081 · Cited by 96
The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9
Emmer, B. T., Hesketh, G. G., Kotnik, E., Tang, V. T., Lascuna, P. J., Xiang, J., Gingras, A.-C., Chen, X.-W., & Ginsburg, D. (2018) · eLife · doi:10.7554/elife.38839 · Cited by 96
Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
Glerup, S., Schulz, R., Laufs, U., & Schlüter, K. (2017) · Basic Research in Cardiology · doi:10.1007/s00395-017-0619-0 · Cited by 95
Metadata
- Authors
- Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- The University of Texas Health Science Center at Houston (US)
- Howard Hughes Medical Institute (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1264-1272
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2067539811
- Semantic Scholar
- 5cb1ad66116f87a0743739413b3b5f7f633657f8
- Cited by
- 3,181
- References
- 27
- Citations by year
- 2026: 130 · 2025: 121 · 2024: 150 · 2023: 182 · 2022: 169 · 2021: 175 · 2020: 193 · 2019: 180 · 2018: 210 · 2017: 229 · 2016: 235 · 2015: 244 · 2014: 171 · 2013: 145 · 2012: 126
- FWCI
- 104.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- W. M. Keck Foundation
- Donald W. Reynolds Foundation
- National Institutes of Health (n01hc55021-47-0-1, n01hc55020-39-0-0, n01hc55016-37-0-0, n01hc055022-024, n01hc55019-35-0-1, n01hc55018-38-0-1, N01-HC55020, N01-HC-55021, HL20948, N01-HC-55019, N01-HC-55022, N01-HC55016, N01-HC55018, N01-HC-55015, n01hc55015-48-0-1)
- National Heart, Lung, and Blood Institute (N01-HC55022, N01-HC-55018, HL-20948, N01 HC 55020, N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022, N01 HC 55019, N01-HC55016, P01HL020948, N01‐HC‐55015, N01-HC55021)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- PCSK9, LDL cholesterol, coronary artery disease, myocardial infarction, coronary revascularization, nonsense mutation, genetic variants, LDL cholesterol lowering, cardiovascular risk, Atherosclerosis Risk in Communities Study, black and white populations
- MeSH terms
- Proprotein Convertase 9, Black or African American, Carotid Arteries, Coronary Disease, Female, Gene Frequency, Genotype, Humans, Hypolipoproteinemias, Cholesterol, LDL, Male, Middle Aged, Risk, Serine Endopeptidases, United States, Genetic Variation, Cohort Studies, Incidence, Proportional Hazards Models, Codon, Nonsense, Proprotein Convertases, Black People, White People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
